Literature DB >> 1400355

Crystal structure of recombinant human interleukin-4.

M R Walter1, W J Cook, B G Zhao, R P Cameron, S E Ealick, R L Walter, P Reichert, T L Nagabhushan, P P Trotta, C E Bugg.   

Abstract

The crystal structure of recombinant human interleukin-4 (rhuIL-4) was initially determined at 3.5-A resolution by multiple isomorphous replacement techniques and subsequently refined to a resolution of 2.35 A by simulated annealing. The final crystallographic R-factor, based on all data in the range 6.0-2.35 A (7470 reflections), is 0.232. Bond lengths and bond angles in the molecule have root mean square deviations from ideal values of 0.016 A and 2.4 degrees, respectively. The overall structure is highly compact and globular with a predominantly hydrophobic core. The main structural feature of rhuIL-4 is a four alpha-helix bundle, which composes approximately 58% of the structure. The helices are arranged in a left-handed antiparallel bundle with two overhand connections. Within these connections is a two-stranded antiparallel beta-sheet. Both the tertiary and secondary structures of rhuIL-4 are similar to those of human granulocyte-macrophage colony-stimulating factor. Critical regions for receptor binding are proposed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400355     DOI: 10.2210/pdb2int/pdb

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Influence of non-bonded parameters on the quality of NMR structures: a new force field for NMR structure calculation.

Authors:  J P Linge; M Nilges
Journal:  J Biomol NMR       Date:  1999-01       Impact factor: 2.835

2.  Improving the quality of protein structures derived by NMR spectroscopy.

Authors:  Christian A E M Spronk; Jens P Linge; Cornelis W Hilbers; Geerten W Vuister
Journal:  J Biomol NMR       Date:  2002-03       Impact factor: 2.835

3.  Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

4.  De novo design of an IL-4 antagonist and its structure at 1.9 A.

Authors:  Sherry L Laporte; Charles M Forsyth; Brian C Cunningham; Larry J Miercke; David Akhavan; Robert M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

5.  Enthalpic and entropic contributions mediate the role of disulfide bonds on the conformational stability of interleukin-4.

Authors:  Daniela C Vaz; J Rui Rodrigues; Walter Sebald; Christopher M Dobson; Rui M M Brito
Journal:  Protein Sci       Date:  2006-01       Impact factor: 6.725

Review 6.  The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals--a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

7.  Gamma chain receptor interleukins: evidence for positive selection driving the evolution of cell-to-cell communicators in the mammalian immune system.

Authors:  Mary J O'Connell; James O McInerney
Journal:  J Mol Evol       Date:  2005-10-04       Impact factor: 2.395

8.  Comprehensive clarification of two paralogous interleukin 4/13 loci in teleost fish.

Authors:  Maki Ohtani; Nobuhiro Hayashi; Keiichiro Hashimoto; Teruyuki Nakanishi; Johannes Martinus Dijkstra
Journal:  Immunogenetics       Date:  2008-06-17       Impact factor: 2.846

9.  Role of the C-terminus in the activity, conformation, and stability of interleukin-6.

Authors:  L D Ward; A Hammacher; J G Zhang; J Weinstock; K Yasukawa; C J Morton; R S Norton; R J Simpson
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

10.  Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding.

Authors:  A Wlodawer; A Pavlovsky; A Gustchina
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.